PEOPLE - ExonHit Therapeutics (Brunel, Paris) makes appointment:
This article was originally published in Clinica
Diagnostics and drug discovery firm ExonHit Therapeutics (Brunel, Paris) has appointed Deborah Smeltzer as a member of its supervisory board. Ms Smeltzer is vice-president of operations and CFO at biopharma firm Dynavax Technologies (California). Her more than 20 years' operating and financial expertise covers the markets of biotechnology (in Europe and the US), genomic analysis, diagnostics and vaccines.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.